GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Enterprise Value

Harrow (Harrow) Enterprise Value : $483.5 Mil (As of Apr. 30, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Harrow Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Harrow's Enterprise Value is $483.5 Mil. Harrow's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.4 Mil. Therefore, Harrow's EV-to-EBIT ratio for today is -202.64.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Harrow's Enterprise Value is $483.5 Mil. Harrow's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $10.0 Mil. Therefore, Harrow's EV-to-EBITDA ratio for today is 48.57.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Harrow's Enterprise Value is $483.5 Mil. Harrow's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $130.2 Mil. Therefore, Harrow's EV-to-Revenue ratio for today is 3.71.


Harrow Enterprise Value Historical Data

The historical data trend for Harrow's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Enterprise Value Chart

Harrow Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 189.35 167.27 259.37 451.36 501.27

Harrow Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 451.36 785.49 723.86 620.12 501.27

Competitive Comparison of Harrow's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harrow's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harrow's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Harrow's Enterprise Value falls into.



Harrow Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Harrow's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Harrow's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harrow  (NAS:HROW) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Harrow's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=483.489/-2.386
=-202.64

Harrow's current Enterprise Value is $483.5 Mil.
Harrow's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.4 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Harrow's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=483.489/9.954
=48.57

Harrow's current Enterprise Value is $483.5 Mil.
Harrow's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.0 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Harrow's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=483.489/130.193
=3.71

Harrow's current Enterprise Value is $483.5 Mil.
Harrow's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $130.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harrow Enterprise Value Related Terms

Thank you for viewing the detailed overview of Harrow's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Harrow (Harrow) Business Description

Traded in Other Exchanges
N/A
Address
102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205
Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.
Executives
Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

Harrow (Harrow) Headlines

From GuruFocus

Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023

By Business Wire Business Wire 04-27-2023